This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GDF9 / Growth/differentiation factor 9 · IHC design guide
Design Immunohistochemistry for GDF9
Plan chromogenic GDF9 IHC on paraffin sections using ovarian follicles as a staining reference (HPA tissue IHC). This guide covers fixation consistency, antibody titration at 1:100–1:300 (datasheet), and interpretation of a secreted, processed protein (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GDF9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Secreted; tissue compartment unresolved (UniProt; HPA tissue IHC) | |
| Staining pattern | Low in ovarian follicle cells; compartment unspecified (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Testis | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across samples (standard IHC practice; not target-specific) | |
| Caveat | Secretion may separate staining from the producing cells (UniProt) | |
| Regulation | Follicle-associated expression (HPA tissue IHC) | |
| Isoform / epitope | No isoforms; propeptide versus mature-chain epitope matters (UniProt) |
Section 1
Recommended GDF9 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by 3 published ovarian IHC protocols (PMC4366263; PMC13110486; PMC4771171).
| Sample | Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A01466-1) |
| Fixation | Image fixative and duration unreported (datasheet A01466-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-GDF9, 1:100-1:300 (datasheet A01466-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GDF9-positive staining in peritubular cells of testis (HPA tissue IHC: Medium). HPA tissue profile: Expression in ovarian follicles. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval rule); adjust for the published sample and detection method.
Section 2
What Is the Expected GDF9 Staining Pattern?
GDF9 is a secreted protein with no transmembrane segment (UniProt O60383). In paraffin IHC, expect follicle-associated staining: UniProt reports protein in primary-follicle oocytes and expression in granulosa cells, while HPA reports low staining in ovarian follicle cells and medium staining in testicular peritubular cells (UniProt O60383; HPA tissue IHC). HPA rates its tissue evidence Supported and cautions that secretion complicates RNA–protein comparisons (HPA tissue IHC).
| Follicle-associated ovarian staining, potentially including oocytes and follicle cells. | This fits the reported ovarian distribution (UniProt O60383; HPA tissue IHC). HPA calls follicle-cell staining low; it gives no separate oocyte intensity, so score those cells separately (HPA tissue IHC). |
| Medium staining in testicular peritubular cells. | This matches an observed HPA IHC pattern and can serve as a tissue-level comparison (HPA tissue IHC). It does not establish that every compartment or neighboring testicular cell should stain. |
| Strong nuclear-only staining, or a sharp plasma-membrane rim without a follicle-associated pattern. | Treat this as suspect localisation and check controls. UniProt describes GDF9 as secreted, with no transmembrane segment; HPA's approved ICC-IF locations are Golgi and cytosol (UniProt O60383; HPA subcellular). Those IF locations are not a paraffin-IHC compartment standard. |
| Staining concentrated in cells HPA lists as not detected, or in unexpected cells within a section. | Investigate cross-reactivity, endogenous detection activity, and tissue identification before assigning GDF9. HPA's negative calls apply to specified cells in specified tissues, not every cell in those organs (HPA tissue IHC). |
| Diffuse brown haze, or no staining in the expected ovarian follicle or testicular peritubular compartment. | Haze alone is not a cell-specific positive result. Absence may reflect a missing target-bearing structure or a failed IHC run; ovarian follicle-cell signal is only low in HPA, so interpret a negative field against its morphology and run controls (HPA tissue IHC). |
💡Expected GDF9 appearanceCall a section positive when staining follows ovarian follicles or testicular peritubular cells, with low follicle-cell or medium peritubular signal as HPA references; uniform haze or isolated nuclear staining is suspect (UniProt O60383; HPA tissue IHC; HPA subcellular).
| Secretion and processing | GDF9 has a signal peptide, propeptide, and mature chain, and is secreted (UniProt O60383). Signal need not remain confined to the producing cell; assess follicle context rather than assuming every adjacent extracellular deposit is specific. |
| Tissue and cell selection | UniProt reports primary-follicle oocytes and ovarian granulosa-cell expression; HPA reports ovarian-follicle staining and low follicle-cell signal (UniProt O60383; HPA tissue IHC). Confirm that the sampled section contains follicles before treating it as an ovarian negative. |
| Protein evidence versus RNA | HPA calls RNA tissue-enhanced in epididymis and testis but warns that secreted-protein location may differ from RNA location (HPA tissue IHC). Use the stated protein IHC observations for slide expectations, not RNA enrichment as a staining-intensity scale. |
| Antibody evidence and retrieval | HPA lists HPA069146 as IHC Supported, without an Enhanced designation (HPA antibodies). The supplied sources give no GDF9-specific retrieval condition or fixation sensitivity; use the IHC-validated antibody's protocol and optimise retrieval with run controls. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in an ovarian section | The examined field may lack follicles, or low follicle-cell signal may be hard to distinguish from background (HPA tissue IHC). | Locate intact follicles on the counterstained section; compare an appropriate positive tissue and run controls before changing the IHC conditions. |
| No signal in a testis comparison | The expected medium HPA signal is specifically in peritubular cells; scoring other cells can give a misleading negative (HPA tissue IHC). | Identify peritubular cells morphologically. If they are present but unstained, check antibody, retrieval, detection, and control-slide performance as general IHC troubleshooting. |
| Widespread brown background | A diffuse deposit without the reported cell pattern may reflect nonspecific antibody binding or endogenous chromogenic detection activity (HPA tissue IHC for expected pattern). | Compare reagent-omission and detection controls; review blocking, washes, antibody concentration, and chromogen development as general IHC steps. |
| Strong staining in a listed negative cell type | Cross-reactivity or endogenous activity is possible; HPA reports not detected only for the named cell types and tissues (HPA tissue IHC). | Verify cell identity and control reactions, then compare the pattern with follicle or peritubular staining before calling it GDF9-specific. |
| Predominantly nuclear or sharply membranous signal | This conflicts with the secreted, non-transmembrane annotation and the approved Golgi/cytosol ICC-IF locations (UniProt O60383; HPA subcellular). | Check morphology and controls, then reassess antibody and detection conditions; do not impose the ICC-IF compartment pattern as a required IHC result. |
| What should an IF/ICC image show? | HPA reports Golgi as the main location and cytosol as an additional location in ICC-IF (HPA subcellular). | Interpret that result on the separate IF/ICC guide page. Its approved localisation supports an IF comparison, but supplies no IF protocol or paraffin-IHC intensity threshold (HPA subcellular). |
Experiment evidence
IHC & IF images showing GDF9 staining
A01466-1 · IHCImmunohistochemistry validation of GDF9 using Anti-GDF-9 Antibody (A01466-1). Immunohistochemical analysis of paraffin-embedded human lung c
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000164404-GDF9/tissue/cerebral+cortex#imid_19042959
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000164404-GDF9/tissue/colon#imid_19044457
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000164404-GDF9/tissue/liver#imid_19044442
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000164404-GDF9/tissue/kidney#imid_19044459
HPA · ICC-IF JURKATHuman Protein Atlas immunofluorescence, JURKAT, antibody HPA069146; green = GDF9, blue = nucleus, red = microtubules.
HPA · ICC-IF JURKATHuman Protein Atlas immunofluorescence, JURKAT, antibody HPA069146; green = GDF9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GDF9 IHC & IF
🧪Run testis first and assess staining in peritubular cells (HPA: Medium in testis peritubular cells). Use adipose tissue as a negative tissue and assess adipocytes (HPA: Not detected in adipocytes); neighboring cells without target staining on the testis slide can help assess background, but they are not a validated internal negative.
Positive control tissue: Testis (Peritubular cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show GDF9 in JURKAT, U2OS, with annotated localisation: Golgi apparatus (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and isotype at the same concentration; and, if available, a GDF9 knockout specimen or a validated immunizing-peptide block. For chromogenic testis IHC, block endogenous peroxidase and check blood-containing regions for background; if using biotin-based detection, control for endogenous biotin.
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the fixative in the selected A01466-1 paraffin-section caption is unreported (selected-SKU tissue-IHC caption: fixative not stated). Antigen-retrieval dependence is unreported; compare staining with and without heat-induced retrieval during optimization. The supplied evidence does not establish whether frozen sections or IF are easier, or identify a testis-specific artefact; interpret extracellular staining cautiously because GDF9 is secreted (UniProt O60383: Secreted).
HPA tissue IHC evidence for GDF9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Peritubular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced GDF9 IHC Tips
These questions address GDF9 staining in paraffin sections with chromogenic detection; the immunofluorescence entry covers the separate IF/ICC application.
How should I optimize retrieval when GDF9 staining is weak in paraffin sections?
Start with citrate pH 6.0 heat retrieval at 95–98 °C for 20 min (page retrieval setting). Keep section thickness, heating, and cooling consistent across runs so a change in signal can be attributed to retrieval (general IHC practice). If staining remains weak, test a shorter or longer heating interval on adjacent sections; consider EDTA pH 9.0 only as a fallback (general IHC practice). Compare staining in follicles with background in adjacent tissue, since GDF9 is reported in ovarian follicles (HPA tissue IHC). Excessive heating can damage morphology and create misleading diffuse signal, so assess tissue preservation alongside intensity (general IHC practice).
Could fixation explain inconsistent GDF9 staining between paraffin blocks?
Target-specific fixation sensitivity for GDF9 is unknown because no fixation condition is reported for the selected antibody’s paraffin-section image (A01466-1 tissue-IHC caption). Record the fixative and actual fixation time for each block, then compare sections processed and retrieved together (general IHC practice). If new samples are available, standardize collection-to-fixation delay and use the same fixation schedule across specimens (general IHC practice). A 10% neutral buffered formalin workflow can provide a consistent starting condition, but its suitability for this epitope still requires testing (general IHC practice). Do not assign weak staining to fixation until retrieval, antibody conditions, and tissue integrity have also been checked (general IHC practice).
Which GDF9 staining pattern should count as plausible in ovarian sections?
Interpret follicle-associated staining in anatomical context: GDF9 protein is reported in oocytes of primary follicles and expression in granulosa cells (UniProt O60383 tissue specificity). Tissue IHC reports expression in ovarian follicles, with low staining in follicle cells (HPA tissue IHC). GDF9 is secreted and has no transmembrane segment, so signal need not form a continuous cell-surface outline (UniProt O60383 subcellular location and topology). Golgi and cytosolic locations have also been observed by ICC/IF, although those observations do not define a required chromogenic tissue pattern (HPA subcellular). Compare cell-associated and extracellular staining against morphology and controls before assigning a source cell (general IHC practice).
How can processing or epitope placement change what GDF9 IHC detects?
GDF9 has a signal peptide at residues 1–24, a propeptide at 25–319, and a mature chain at 320–454 (UniProt O60383 processing). It also has six annotated glycosylation sites, including residue 338 in the mature chain (UniProt O60383 glycosylation). No isoforms are listed, so a staining difference should not be assigned to an alternative isoform without further evidence (UniProt O60383 isoforms). Determine whether the antibody’s documented epitope lies in the propeptide or mature chain before interpreting which processed form a positive cell contains (UniProt O60383 processing; general IHC practice). If the epitope is unspecified, report GDF9 immunoreactivity without naming a molecular form (general IHC practice).
How should I adapt a GDF9 study to multiplex immunofluorescence?
Use this entry to plan the separate IF/ICC application; the selected antibody’s tissue image documents paraffin-section IHC at 1:100 and does not establish an IF dilution (A01466-1 tissue-IHC caption). Pair GDF9 with a validated marker that identifies the expected oocyte or follicle-cell population in the specimen (UniProt O60383 tissue specificity; general IF practice). Choose spectrally separated fluorophores and place the weaker channel away from prominent tissue autofluorescence, checking unstained sections first (general IF practice). For intracellular Golgi or cytosolic epitopes, test gentle permeabilisation; for an accessible extracellular epitope, compare a nonpermeabilised condition (HPA subcellular; UniProt O60383 secreted location; general IF practice). Include single-stain controls to distinguish signal from bleed-through (general IF practice).
How can I reduce diffuse or brown background without losing follicular GDF9 signal?
First inspect a no-primary section to identify background from the detection system rather than antibody binding (general IHC practice). In a peroxidase and DAB workflow, block endogenous peroxidase before applying the primary antibody and use the same development time across sections (general IHC practice). The selected antibody was shown at 1:100 in a paraffin-section image; treat that as a documented starting dilution, not proof of the best concentration for every specimen (A01466-1 tissue-IHC caption). Titrate around that starting point and adjust blocking or wash stringency while retaining follicle-associated signal (HPA tissue IHC; general IHC practice). Assess deposits, folds, and section edges separately from cellular staining (general IHC practice).
What is a defensible way to quantify GDF9 staining across follicles? ⚠ ANSWER MARKED FOR VERIFICATION
Define the compartment and eligible cells before scoring, since GDF9 is secreted and follicle-associated staining may include more than one location (UniProt O60383 subcellular location; HPA tissue IHC). For cell-associated chromogenic signal, record the percentage positive and intensity, then calculate an H-score from 0–300 if the intensity categories are prespecified (general IHC practice). For spatial comparisons, report positive-cell density per mm² within a consistently drawn follicular region (general IHC practice). Normalize to the number of eligible cells or the measured region area, and stratify by follicle stage where identifiable (general IHC practice). Keep retrieval, DAB development, imaging, and scoring rules consistent across groups (general IHC practice).
What distinguishes convincing GDF9 staining from artefact in a chromogenic section?
Give greatest weight to reproducible staining that follows intact follicular anatomy, because ovarian follicles are a reported GDF9 tissue location (HPA tissue IHC). Check the stained cell against the documented oocyte and granulosa-cell context before calling it a source of GDF9 (UniProt O60383 tissue specificity). GDF9 is secreted and lacks a transmembrane segment, so an exclusively sharp membrane outline deserves closer scrutiny (UniProt O60383 subcellular location and topology). Exclude necrotic areas, section edges, folds, and precipitate from interpretation, and compare with a no-primary control for endogenous enzyme signal (general IHC practice). Report compartment and cell type separately when extracellular staining makes the producer uncertain (general IHC practice).
Boster reagents
Best GDF9 / Growth/differentiation factor 9 IHC Antibodies
A01466-1 has an IHC figure from paraffin-embedded human lung cancer (IHC image caption); IF is listed, but no IF figure is supplied (catalog applications; catalog IF images).
Real IHC data
Anti-GDF-9 Antibody
Cat # A01466-1
A01466-1 will render with an IHC figure from paraffin-embedded human lung cancer at 1:100 (IHC image caption). The catalog lists IHC and IF applications and Human and Mouse reactivity, but supplies no IF figure (catalog applications; catalog reactivity; catalog IF images).
Which to pick: Choose A01466-1 for paraffin-section IHC, starting within its listed 1:100–1:300 range; its own figure shows paraffin-embedded human lung cancer, with fixative unreported (datasheet: IHC 1:100–1:300; IHC image caption). For IF, A01466-1 lists 1:50, but the catalog supplies no IF figure or separate ICC validation (catalog IF dilution; catalog IF images; catalog applications). It is the catalog option for Human or Mouse samples because both are listed as reactive; the antibody is polyclonal, and the supplied IHC figure documents Human tissue only (catalog reactivity; datasheet: Polyclonal; IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O60383 (GDF9_HUMAN, Growth/differentiation factor 9).
- Human Protein Atlas. GDF9 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. GDF9 subcellular location (ICC-IF): Mainly localized to the Golgi apparatus. In addition localized to the cytosol..
- Human Protein Atlas. GDF9 antibody validation summary (1 antibodies).
- GDF9 is transiently expressed in oocytes before follicle formation in the human fetal ovary and is regulated by a novel NOBOX transcript. PloS one 2015 — PMC4366263.
- Cryoprotectant-dependent preservation of cellular viability and oocyte-secreted factors in slow-frozen feline ovarian tissue. Veterinary world 2026 — PMC13110486.
- The effect of kisspeptin on the maturation of human ovarian follicles in culture following vitrification-thawing processes. JBRA assisted reproduction 2023 — PMC10718532.
- Tribulus terrestris Alters the Expression of Growth Differentiation Factor 9 and Bone Morphogenetic Protein 15 in Rabbit Ovaries of Mothers and F1 Female Offspring. PloS one 2016 — PMC4771171.
- PubMed PMID:15372022 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:10443672 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GDF9 (Growth/differentiation factor 9). Expected localisation Secreted; tissue compartment unresolved (UniProt; HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A01466-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Testis (Peritubular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Paraffin-embedded human lung cancer tissue; fixative not specified (datasheet A01466-1); 2. Fixation: Image fixative and duration unreported (datasheet A01466-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-GDF9, 1:100-1:300 (datasheet A01466-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across samples (standard IHC practice; not target-specific); Caveat: Secretion may separate staining from the producing cells (UniProt); Isoform / epitope: No isoforms; propeptide versus mature-chain epitope matters (UniProt); Regulation: Follicle-associated expression (HPA tissue IHC). Evidence: UniProt O60383, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the Golgi apparatus. In addition localized to…, Datasheet A01466-1, PMC4366263, PMC13110486. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GDF9/immunohistochemistry-ihc-guide.